Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

被引：0
|
作者：
Bruera, Gemma
Massacese, Silvia
Pepe, Francesco
Malapelle, Umberto
Dal Mas, Antonella
Ciacco, Eugenio
Calvisi, Giuseppe
Marchetti, Paolo
Troncone, Giancarlo
Simmaco, Maurizio
Ricevuto, Enrico
机构：
[1] Univ Aquila, S Salvatore Hosp, Dept Biotechnol & Appl Clin Sci, Oncol Territorial Care,Oncol Network ASL1 Abruzzo, Laquila, Italy
[2] S Salvatore Hosp, Pharm Unit, Oncol Network ASL1 Abruzzo, Laquila, Italy
[3] Univ Federico II, Dept Publ Hlth, Naples, Italy
[4] S Salvatore Hosp, Oncol Network ASL1 Abruzzo, Pathol, Laquila, Italy
[5] Sapienza Univ Rome, S Andrea Hosp, Rome, Italy
[6] S Andrea Hosp, Adv Mol Diagnost, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e15517
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15517
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
    Battaglin, Francesca
    Schirripa, Marta
    Buggin, Federica
    Pietrantonio, Filippo
    Morano, Federica
    Boscolo, Giorgia
    Tonini, Giuseppe
    Lutrino, Eufemia Stefania
    Lucchetti, Jessica
    Salvatore, Lisa
    Passardi, Alessandro
    Cremolini, Chiara
    Arnoldi, Ermenegildo
    Scartozzi, Mario
    Pella, Nicoletta
    Boni, Luca
    Bergamo, Francesca
    Zagonel, Vittorina
    Loupakis, Fotios
    Lonardi, Sara
    BMC CANCER, 2018, 18
  • [32] The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
    Francesca Battaglin
    Marta Schirripa
    Federica Buggin
    Filippo Pietrantonio
    Federica Morano
    Giorgia Boscolo
    Giuseppe Tonini
    Eufemia Stefania Lutrino
    Jessica Lucchetti
    Lisa Salvatore
    Alessandro Passardi
    Chiara Cremolini
    Ermenegildo Arnoldi
    Mario Scartozzi
    Nicoletta Pella
    Luca Boni
    Francesca Bergamo
    Vittorina Zagonel
    Fotios Loupakis
    Sara Lonardi
    BMC Cancer, 18
  • [33] First-line panitumumab (P) plus capecitabine (C) for the treatment of elderly patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Preliminary results of the phase II, PANEL GITuD-2011-01 study
    Mendez Mendez, J. C.
    Ramos, M.
    De la Camara Gomez, J. C.
    Pellon, M. L.
    Covela, M.
    Quintero Aldana, G. A.
    Salgado Fernandez, M.
    Fernandez-Montes, A.
    Reboredo, M.
    Valladares-Ayerbes, M.
    Jorge Fernandez, M.
    Gonzalez Villarroel, P.
    Romero Reinoso, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy
    Tsuji, A.
    Nakamura, M.
    Watanabe, T.
    Manaka, D.
    Matsuoka, H.
    Kataoka, M.
    Takeuchi, M.
    Ichikawa, W.
    Fujii, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
    Brodowicz, T.
    Ciuleanu, T. E.
    Radosavljevic, D.
    Shacham-Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Mrsic-Krmpotic, Z.
    Dank, M.
    Purkalne, G.
    Messinger, D.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1769 - 1777
  • [36] A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer (CIRIS study): overall survival analysis
    Eto, T.
    Masuishi, T.
    Matsui, T.
    Anzai, S.
    Suzuki, Y.
    Fukami, Y.
    Suzuki, K.
    Kusano, F.
    Sakai, Y.
    Tazawa, J.
    ANNALS OF ONCOLOGY, 2015, 26
  • [37] Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
    De Stefano, A.
    Giuliani, F.
    Nasti, G.
    Montesarchio, V.
    Santabarbara, G.
    Leo, S.
    Malapelle, U.
    Rosati, G.
    Lolli, I.
    Tamburini, E.
    Colombo, A.
    Santini, D.
    Silvestro, L.
    Leone, A.
    Vitagliano, C.
    Troncone, G.
    Sobrero, A.
    Giannarelli, D.
    Budillon, A.
    Avallone, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S172 - S173
  • [38] Anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer: A single-arm, phase II study (ALTER-C-002 trial).
    Ding Ke-Feng
    Liu Yue
    Chen Jiaqi
    Sun Lifeng
    Xu Dong
    Liao Xiujun
    Xiao Qian
    Li Jun
    Yuan Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [39] Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)
    De Stefano, A.
    Nasti, G.
    Febbraro, A.
    Rosati, G.
    Giuliani, F.
    Santini, D.
    Aprile, G.
    Scartozzi, M.
    Silvestris, F.
    Luppi, G.
    Lolli, I.
    Mastroianni, C.
    Leo, S.
    Montesarchio, V.
    Gridelli, C.
    Pozzo, C.
    Sperti, E.
    Giannarelli, D.
    Budillon, A.
    Avallone, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Worse prognosis of KRAS C.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with first-line triplet chemotherapy plus bevacizumab (FIr-B/FOx) and post-progression
    Bruera, Gemma
    Cannita, Katia
    Di Giacomo, Daniela
    Lamy, Aude
    Giordano, Aldo Victor
    Vicentini, Roberto
    Marchetti, Paolo
    Frebourg, Thierry
    Sabourin, Jean-Christophe
    Tosi, Mario
    Alesse, Edoardo
    Ficorella, Corrado
    Ricevuto, Enrico
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345